Whilst racking up 50 novel drug approvals, the FDA approved fewer than it did in 2023, when there were 55 greenlit to market. Conversely, the EMA’s 2024 figure of 46 was a step up from the 39 ...

Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approval, Epidemiology, Medication, Pipeline and Companies by DelveInsight ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

The EU originally had approved the drugs in question based primarily on clinical trials conducted in Hyderabad by GVK Biosciences, a contract research organization based there, on behalf of ...

The drug, which is still being reviewed by the EMA, provides direct competition to Eisai and Biogen’s Leqembi (lecanemab), which the EMA approved in late 2024, more than a year later than the FDA.